Cristin-resultat-ID: 1876773
Sist endret: 3. februar 2021, 11:36
NVI-rapporteringsår: 2020
Resultat
Vitenskapelig artikkel
2020

Identification and Tracking of Antiviral Drug Combinations

Bidragsytere:
  • Aleksandr Ianevski
  • Rouan Yao
  • Svetlana Biza
  • Eva Zusinaite
  • Andres Mannik
  • Gaily Kivi
  • mfl.

Tidsskrift

Viruses
ISSN 1999-4915
e-ISSN 1999-4915
NVI-nivå 1

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2020
Publisert online: 2020
Volum: 12
Hefte: 10
Open Access

Importkilder

Scopus-ID: 2-s2.0-85093523784

Beskrivelse Beskrivelse

Tittel

Identification and Tracking of Antiviral Drug Combinations

Sammendrag

Combination therapies have become a standard for the treatment for HIV and hepatitis C virus (HCV) infections. They are advantageous over monotherapies due to better efficacy, reduced toxicity, as well as the ability to prevent the development of resistant viral strains and to treat viral co-infections. Here, we identify new synergistic combinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), echovirus 1 (EV1), hepatitis C virus (HCV) and human immunodeficiency virus 1 (HIV-1) in vitro. We observed synergistic activity of nelfinavir with convalescent serum and with purified neutralizing antibody 23G7 against SARS-CoV-2 in human lung epithelial Calu-3 cells. We also demonstrated synergistic activity of nelfinavir with EIDD-2801 or remdesivir in Calu-3 cells. In addition, we showed synergistic activity of vemurafenib with emetine, homoharringtonine, anisomycin, or cycloheximide against EV1 infection in human lung epithelial A549 cells. We also found that combinations of sofosbuvir with brequinar or niclosamide are synergistic against HCV infection in hepatocyte-derived Huh-7.5 cells, and that combinations of monensin with lamivudine or tenofovir are synergistic against HIV-1 infection in human cervical TZM-bl cells. These results indicate that synergy is achieved when a virus-directed antiviral is combined with another virus- or host-directed agent. Finally, we present an online resource that summarizes novel and known antiviral drug combinations and their developmental status.

Bidragsytere

Aleksandr Ianevski

  • Tilknyttet:
    Forfatter
    ved Institutt for klinisk og molekylær medisin ved Norges teknisk-naturvitenskapelige universitet

Rouan Yao

  • Tilknyttet:
    Forfatter
    ved Institutt for klinisk og molekylær medisin ved Norges teknisk-naturvitenskapelige universitet

Svetlana Biza

  • Tilknyttet:
    Forfatter
    ved Institutt for klinisk og molekylær medisin ved Norges teknisk-naturvitenskapelige universitet

Eva Zusinaite

  • Tilknyttet:
    Forfatter
    ved Tartu Ülikool

Andres Mannik

  • Tilknyttet:
    Forfatter
    ved Estland
1 - 5 av 26 | Neste | Siste »